Hannah England (Freeman) Named a Law360 Life Sciences MVP

Practices: Intellectual Property, Intellectual Property Transactions, IP Structuring in M&A, Spinouts & Reorganizations, Strategic Licensing Programs, Joint Ventures, Collaborations and Alliances, Strategic Commercial Agreements, Digital Health, Venture Capital & Emerging Companies

Life sciences licensing partner Hannah England (Freeman) (Boston) was profiled in Law360 as a life sciences MVP. Hannah represented clients in five of the top 15 biopharmaceutical licensing deals of 2020 measured by deal value, according to an analysis published in Fierce Biotech. 

Her accomplishments include advising Dutch biotech company UniQure NV's gene therapy licensing deal with CSL Behring for hemophilia B patients. She steered Takeda Pharmaceutical’s partnership with Neurocrine Biosciences, which will allow Takeda to further develop and market potential therapies for psychiatric disorders. She also advised Belgian biopharmaceutical company iTeos Therapeutics in a collaboration with global healthcare leader GSK to co-develop and co-commercialize a monoclonal antibody currently in development as a potential treatment for patients with cancer. 

In the article, Hannah notes that many of her client relationships are longstanding. Those relationships include companies ranging in size from large, established pharmaceutical companies, through innovative, younger biotech companies. 

The Law360 MVP award honor exceptional lawyers who secured “hard-earned successes in high-stakes litigation, complex global matters and record-breaking deals.”


Cookie Settings